Probiotic and commensal gut microbial therapies in multiple sclerosis and its animal models: a comprehensive review.
Probiotic and commensal gut microbial therapies in multiple sclerosis and its animal models: a comprehensive review.
复制标题
DOI：
10.1080/19490976.2021.1943289
复制
发表时间：
2021-01
期刊：
影响因子：
12.2
通讯作者：
Krementsov DN
中科院分区：
文献类型：
--
作者：
Blais LL;Montgomery TL;Amiel E;Deming PB;Krementsov DN
对多发性硬化症（MS）替代疗法的需求引发了大量关于微生物疗法的研究，这些研究的重点是操纵微生物-肠道-脑轴。本综合综述旨在采用Bradford Hill标准（BHC）作为多参数评估标准，对目前各种益生菌和共生肠道微生物治疗多发性硬硬症的临床和临床前证据进行系统评价。通过文献检索，共发现37项相关研究（6项人体研究，31项动物研究），其中28项益生菌治疗研究和9项共生治疗研究。除了对这些发现进行定性总结外，还使用BHC对每种细菌制剂的治疗证据进行了评估，以产生总结性评分。这些评分包括研究质量、重复性和其他考虑因素，用于对最有希望的治疗方法进行排名，并突出缺陷。几种治疗制剂，包括VSL#3、副干酪乳杆菌、动物双歧杆菌、大肠杆菌尼索尔1917和历史普雷沃氏菌，被认为是最有希望的。相比之下，许多其他疗法受到可复制发现和其他标准的有限证据的阻碍，这些需要通过未来的研究来解决，以便利用肠道微生物疗法最终为MS提供更便宜，更安全，更持久的治疗。
The need for alternative treatments for multiple sclerosis (MS) has triggered copious amounts of research into microbial therapies focused on manipulating the microbiota–gut–brain axis. This comprehensive review was intended to present and systematically evaluate the current clinical and preclinical evidence for various probiotic and commensal gut microbial therapies as treatments for MS, using the Bradford Hill criteria (BHC) as a multi-parameter assessment rubric. Literature searches were performed to identify a total of 37 relevant studies (6 human, 31 animal), including 28 probiotic therapy and 9 commensal therapy studies. In addition to presenting qualitative summaries of these findings, therapeutic evidence for each bacterial formulation was assessed using the BHC to generate summative scores. These scores, which encompassed study quality, replication, and other considerations, were used to rank the most promising therapies and highlight deficiencies. Several therapeutic formulations, including VSL#3, Lactobacillus paracasei, Bifidobacterium animalis, E. coli Nissle 1917, and Prevotella histicola, emerged as the most promising. In contrast, a number of other therapies were hindered by limited evidence of replicable findings and other criteria, which need to be addressed by future studies in order to harness gut microbial therapies to ultimately provide cheaper, safer, and more durable treatments for MS.
登录
查看更多内容
DOI：
10.1006/meth.1996.0123
发表时间：
1996-01-01
期刊：
Methods (Orlando)
影响因子：
--
作者：
Dal Canto, Mauro C.;Kim, Byung S.;Melvold, Roger W.
通讯作者：
Melvold, Roger W.
影响因子：
5.8
作者：
Gajofatto, A.;Bacchetti, P.;Waubant, E.
通讯作者：
Waubant, E.
影响因子：
5.4
作者：
Abdurasulova, I. N.;Matsulevich, A. V.;Suvorov, A. N.
通讯作者：
Suvorov, A. N.
影响因子：
4.6
作者：
Chen J;Chia N;Kalari KR;Yao JZ;Novotna M;Paz Soldan MM;Luckey DH;Marietta EV;Jeraldo PR;Chen X;Weinshenker BG;Rodriguez M;Kantarci OH;Nelson H;Murray JA;Mangalam AK
通讯作者：
Mangalam AK
多发性硬化症患者接受升级与早期强化疾病修饰疗法的临床疗效对比
影响因子：
29
作者：
Harding, Katharine;Williams, Owain;Tallantyre, Emma
通讯作者：
Tallantyre, Emma